Latest filings (excl ownership)
15-12B
Securities registration termination
10 Aug 17
25-NSE
Exchange delisting
31 Jul 17
8-K
Completion of Acquisition or Disposition of Assets
31 Jul 17
RW
Registration withdrawal request
31 Jul 17
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jul 17
8-K
Amendments to Articles of Incorporation or Bylaws
10 Jul 17
8-K
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement
5 Jul 17
DEFA14A
Additional proxy soliciting materials
5 Jul 17
DEFA14A
Additional proxy soliciting materials
30 Jun 17
8-K
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement
19 Jun 17
DEFA14A
Additional proxy soliciting materials
19 Jun 17
8-K
Nexvet Biopharma plc (“Nexvet”) Rule 15 Announcement
16 Jun 17
DEFA14A
Additional proxy soliciting materials
16 Jun 17
DEFA14A
Additional proxy soliciting materials
16 Jun 17
8-K
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement
14 Jun 17
DEFA14A
Additional proxy soliciting materials
14 Jun 17
CT ORDER
Confidential treatment order
13 Jun 17
8-K
Nexvet Biopharma plc (“Nexvet”) Rule 17(b) Announcement
7 Jun 17
DEFA14A
Additional proxy soliciting materials
7 Jun 17
DEFA14A
Additional proxy soliciting materials
5 Jun 17
8-K
Nexvet Biopharma plc (“Nexvet”) Rule 17 Announcement
2 Jun 17
8-K
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement
2 Jun 17
DEFA14A
Additional proxy soliciting materials
2 Jun 17
DEFA14A
Additional proxy soliciting materials
2 Jun 17
DEFM14A
Proxy related to merger
2 Jun 17
8-K
Nexvet Biopharma plc (“Nexvet”) Rule 2.10 Announcement
12 May 17
DEFA14A
Additional proxy soliciting materials
12 May 17
10-Q
2017 Q3
Quarterly report
11 May 17
8-K
Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2017
11 May 17
PREM14A
Preliminary proxy related to merger
11 May 17
8-K
Zoetis to Acquire Nexvet for US$6.72 in Cash Per Share
18 Apr 17
DEFA14A
Additional proxy soliciting materials
18 Apr 17
8-K
Departure of Directors or Certain Officers
13 Mar 17
10-Q
2017 Q2
Quarterly report
10 Feb 17
8-K
Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017
10 Feb 17
8-K
Amendments to Articles of Incorporation or Bylaws
18 Nov 16
10-Q
2017 Q1
Quarterly report
4 Nov 16
8-K
Nexvet Reports Financial Results for First Quarter of Fiscal Year 2017
4 Nov 16
DEF 14A
Definitive proxy
25 Oct 16
PRE 14A
Preliminary proxy
17 Oct 16
Latest ownership filings
SC 13G/A
Nexvet Biopharma plc
13 Feb 18
SC 13D/A
Nexvet Biopharma plc
8 Aug 17
4
Christopher Nigel Brown
2 Aug 17
4
JURGEN HORN
2 Aug 17
4
RAJIV A PATEL
2 Aug 17
4
Geraldine T Farrell
2 Aug 17
4
Mark Heffernan
2 Aug 17
4
Cormac G Kilty
2 Aug 17
4
JOHN BERNARD PAYNE
2 Aug 17
4
Philip D Dreyfuss
2 Aug 17
4
George W Gunn
2 Aug 17
4
Damian T. Lismore
2 Aug 17
4
RICHARD B FRIED
2 Aug 17
4
Ashraf Hanna
2 Aug 17
4
Joseph S McCracken
2 Aug 17
4
Joseph S McCracken
5 Jul 17
4
JOHN BERNARD PAYNE
5 Jul 17
4
Mark Heffernan
5 Jul 17
4
Ashraf Hanna
5 Jul 17
4
Christopher Nigel Brown
5 Jul 17
4
Cormac G Kilty
5 Jul 17
4
RAJIV A PATEL
5 Jul 17
4
Damian T. Lismore
5 Jul 17
4
Geraldine T Farrell
5 Jul 17
4
George W Gunn
5 Jul 17
4
JURGEN HORN
5 Jul 17
SC 13D/A
Nexvet Biopharma plc
19 Apr 17
4
Ashraf Hanna
4 Apr 17
4
George W Gunn
4 Apr 17
4
Joseph S McCracken
4 Apr 17
4
RAJIV A PATEL
3 Apr 17
SC 13G/A
Nexvet Biopharma plc
14 Feb 17
SC 13G/A
Nexvet Biopharma plc
10 Feb 17
SC 13G/A
Nexvet Biopharma plc
9 Feb 17
3
Philip D Dreyfuss
11 Jan 17
3
William Seybold
11 Jan 17
3
Ravi K Paidipaty
11 Jan 17
4
Daniel J. Hirsch
11 Jan 17
SC 13G
Nexvet Biopharma plc
11 Jan 17
4
RAJIV A PATEL
4 Jan 17